HRP20110076T1 - Farmaceutske kombinacije koje sadrže 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i paracetamol - Google Patents
Farmaceutske kombinacije koje sadrže 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i paracetamol Download PDFInfo
- Publication number
- HRP20110076T1 HRP20110076T1 HR20110076T HRP20110076T HRP20110076T1 HR P20110076 T1 HRP20110076 T1 HR P20110076T1 HR 20110076 T HR20110076 T HR 20110076T HR P20110076 T HRP20110076 T HR P20110076T HR P20110076 T1 HRP20110076 T1 HR P20110076T1
- Authority
- HR
- Croatia
- Prior art keywords
- pain
- dimethylamino
- phenol
- propyl
- ethyl
- Prior art date
Links
- KWTWDQCKEHXFFR-UHFFFAOYSA-N 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)CC(C)C(CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-UHFFFAOYSA-N 0.000 title claims abstract 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract 3
- 229960005489 paracetamol Drugs 0.000 title claims abstract 3
- 208000002193 Pain Diseases 0.000 claims abstract 14
- 150000001875 compounds Chemical class 0.000 claims abstract 5
- 239000002552 dosage form Substances 0.000 claims abstract 5
- 208000000094 Chronic Pain Diseases 0.000 claims abstract 3
- 208000005298 acute pain Diseases 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims 3
- KWTWDQCKEHXFFR-RISCZKNCSA-N 3-[(2s,3s)-1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)C[C@@H](C)[C@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-RISCZKNCSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- KWTWDQCKEHXFFR-FZMZJTMJSA-N 3-[(2r,3s)-1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)C[C@H](C)[C@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-FZMZJTMJSA-N 0.000 claims 1
- KWTWDQCKEHXFFR-BXUZGUMPSA-N 3-[(2s,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)C[C@@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-BXUZGUMPSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010045171 Tumour pain Diseases 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06008851 | 2006-04-28 | ||
| PCT/EP2007/003632 WO2007128413A1 (en) | 2006-04-28 | 2007-04-25 | Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110076T1 true HRP20110076T1 (hr) | 2011-02-28 |
Family
ID=37025148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110076T HRP20110076T1 (hr) | 2006-04-28 | 2011-02-01 | Farmaceutske kombinacije koje sadrže 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i paracetamol |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP2012764B1 (ko) |
| JP (2) | JP5496653B2 (ko) |
| KR (1) | KR101396166B1 (ko) |
| CN (1) | CN101431990B (ko) |
| AT (1) | ATE494889T1 (ko) |
| AU (1) | AU2007247481B2 (ko) |
| BR (1) | BRPI0710682B8 (ko) |
| CA (1) | CA2650423C (ko) |
| CY (1) | CY1111369T1 (ko) |
| DE (1) | DE602007011913D1 (ko) |
| DK (1) | DK2012764T3 (ko) |
| EC (2) | ECSP088793A (ko) |
| ES (1) | ES2356093T3 (ko) |
| HK (1) | HK1127289A1 (ko) |
| HR (1) | HRP20110076T1 (ko) |
| IL (1) | IL194883A (ko) |
| MX (1) | MX2008013779A (ko) |
| NO (2) | NO341602B1 (ko) |
| NZ (1) | NZ571442A (ko) |
| PL (1) | PL2012764T3 (ko) |
| PT (1) | PT2012764E (ko) |
| RU (1) | RU2442576C2 (ko) |
| SI (1) | SI2012764T1 (ko) |
| WO (1) | WO2007128413A1 (ko) |
| ZA (1) | ZA200810124B (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007012165A1 (de) | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
| EP3170494A3 (en) * | 2007-11-23 | 2017-09-06 | Grünenthal GmbH | Tapentadol compositions |
| EP2992877A1 (en) | 2010-06-15 | 2016-03-09 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| EP3287123B1 (en) | 2011-03-04 | 2020-04-22 | Grünenthal GmbH | Aqueous pharmaceutical formulation of tapentadol for oral administration |
| EP3025710A1 (en) | 2011-03-04 | 2016-06-01 | Grünenthal GmbH | Parenteral administration of tapentadol |
| US9446008B2 (en) | 2011-03-04 | 2016-09-20 | Gruenenthal Gmbh | Semisolid aqueous pharmaceutical composition containing tapentadol |
| US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| US9855286B2 (en) | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| US20130310435A1 (en) * | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
| WO2016156147A1 (en) | 2015-03-27 | 2016-10-06 | Grünenthal GmbH | Stable formulation for parenteral administration of tapentadol |
| PE20190908A1 (es) | 2016-09-23 | 2019-06-26 | Gruenenthal Chemie | Formulacion estable para la administracion parenteral de tapentadol |
| WO2018153947A1 (en) | 2017-02-23 | 2018-08-30 | Grünenthal GmbH | Tapentadol as local anesthetic |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| HUE033042T2 (en) * | 2002-11-22 | 2017-11-28 | Gruenenthal Gmbh | Combination of selected analgesics with COX II inhibitors |
-
2007
- 2007-04-25 ES ES07724562T patent/ES2356093T3/es active Active
- 2007-04-25 NZ NZ571442A patent/NZ571442A/en unknown
- 2007-04-25 DE DE602007011913T patent/DE602007011913D1/de active Active
- 2007-04-25 JP JP2009506978A patent/JP5496653B2/ja active Active
- 2007-04-25 SI SI200730498T patent/SI2012764T1/sl unknown
- 2007-04-25 AT AT07724562T patent/ATE494889T1/de active
- 2007-04-25 CA CA2650423A patent/CA2650423C/en active Active
- 2007-04-25 MX MX2008013779A patent/MX2008013779A/es active IP Right Grant
- 2007-04-25 RU RU2008146816/15A patent/RU2442576C2/ru active
- 2007-04-25 DK DK07724562.9T patent/DK2012764T3/da active
- 2007-04-25 EP EP07724562A patent/EP2012764B1/en active Active
- 2007-04-25 KR KR1020087028929A patent/KR101396166B1/ko active IP Right Grant
- 2007-04-25 BR BRPI0710682A patent/BRPI0710682B8/pt active IP Right Grant
- 2007-04-25 WO PCT/EP2007/003632 patent/WO2007128413A1/en active Application Filing
- 2007-04-25 PT PT07724562T patent/PT2012764E/pt unknown
- 2007-04-25 CN CN2007800148115A patent/CN101431990B/zh active Active
- 2007-04-25 PL PL07724562T patent/PL2012764T3/pl unknown
- 2007-04-25 AU AU2007247481A patent/AU2007247481B2/en active Active
-
2008
- 2008-10-06 EC EC2008008793A patent/ECSP088793A/es unknown
- 2008-10-23 IL IL194883A patent/IL194883A/en active IP Right Grant
- 2008-10-28 NO NO20084542A patent/NO341602B1/no unknown
- 2008-11-27 ZA ZA200810124A patent/ZA200810124B/xx unknown
-
2009
- 2009-06-25 HK HK09105733.2A patent/HK1127289A1/xx unknown
-
2011
- 2011-02-01 HR HR20110076T patent/HRP20110076T1/hr unknown
- 2011-04-05 CY CY20111100353T patent/CY1111369T1/el unknown
-
2013
- 2013-07-11 JP JP2013145481A patent/JP2013213045A/ja not_active Withdrawn
-
2017
- 2017-01-05 EC ECIEPI2017643A patent/ECSP17000643A/es unknown
- 2017-11-17 NO NO20171831A patent/NO343505B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110076T1 (hr) | Farmaceutske kombinacije koje sadrže 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i paracetamol | |
| HRP20190500T1 (hr) | Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina | |
| HRP20110271T1 (hr) | Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek) | |
| ES2918548T3 (es) | Uso de 5-amino-2,3-dihidro-1,4-ftalazindiona en el tratamiento de esclerosis múltiple progresiva crónica | |
| HRP20151327T1 (hr) | Farmaceutska kombinacija za lijeäśenje boli | |
| EP2275107A3 (en) | Combinations for the treatment of diseases involving cell proliferation | |
| JP2007533686A5 (ko) | ||
| HRP20130213T1 (hr) | Spojevi morfinana | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2010509366A5 (ko) | ||
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| JP2009504763A5 (ko) | ||
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| EP3248602A1 (en) | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae | |
| HRP20140215T1 (hr) | Kombinacija koja sadrži paklitaksel za lijeäśenje raka jajnika | |
| AR058619A1 (es) | Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo | |
| Jiménez-Andrade et al. | Synergistic effects between codeine and diclofenac after local, spinal and systemic administration | |
| CA3065318A1 (en) | Methods for treatment of fibrotic diseases | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| MX2009002311A (es) | Composiciones farmaceuticas para tratamiento de infecciones fungales. | |
| JP2009520010A5 (ko) | ||
| JP2019123731A5 (ko) | ||
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| JP2009533428A (ja) | 筋肉内抗ウイルス処置 | |
| MX2022011240A (es) | Azálidos de urea inmunomoduladores. |